Point Therapeutics Announces Annual Meeting of Stockholders on June 20, 2006 in Boston; Meeting will be Web Cast

Point Therapeutics, Inc. (NASDAQ: POTP) announced that
it will hold its Annual Meeting of Stockholders on June 20, 2006 at
10:30 a.m., Eastern Time. All stockholders are invited to attend the
meeting which will be held at the offices of Ropes & Gray, LLP, One
International Place, 36th Floor, Boston, MA, 02110.
   After completion of the formal portion of the annual meeting, Don
Kiepert, President and CEO, will review company achievements and
discuss future company objectives.
   The meeting will also be Web cast on the company's Web site,
www.pther.com at 10:30 a.m., Eastern Time, June 20, 2006. A replay
will be available on www.pther.com following the meeting.

   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.
In addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes and PT-510 as a
vaccine adjuvant.